Baylor Scott & White Health, Temple, Texas, USA.
Texas A&M University College of Medicine, Temple, Texas, USA.
Clin Infect Dis. 2022 Apr 28;74(8):1329-1337. doi: 10.1093/cid/ciab654.
Evidence for vaccine effectiveness (VE) against influenza-associated pneumonia has varied by season, location, and strain. We estimate VE against hospitalization for radiographically identified influenza-associated pneumonia during 2015-2016 to 2017-2018 seasons in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
Among adults aged ≥18 years admitted to 10 US hospitals for acute respiratory illness (ARI), clinician-investigators used keywords from reports of chest imaging performed during 3 days around hospital admission to assign a diagnosis of "definite/probable pneumonia." We used a test-negative design to estimate VE against hospitalization for radiographically identified laboratory-confirmed influenza-associated pneumonia, comparing reverse transcriptase-polymerase chain reaction-confirmed influenza cases with test-negative subjects. Influenza vaccination status was documented in immunization records or self-reported, including date and location. Multivariable logistic regression models were used to adjust for age, site, season, calendar-time, and other factors.
Of 4843 adults hospitalized with ARI included in the primary analysis, 266 (5.5%) had "definite/probable pneumonia" and confirmed influenza. Adjusted VE against hospitalization for any radiographically confirmed influenza-associated pneumonia was 38% (95% confidence interval [CI], 17-53%); by type/subtype, it was 74% (95% CI, 52-87%) influenza A (H1N1)pdm09, 25% (95% CI, -15% to 50%) A (H3N2), and 23% (95% CI, -32% to 54%) influenza B. Adjusted VE against intensive care for any influenza was 57% (95% CI, 19-77%).
Influenza vaccination was modestly effective among adults in preventing hospitalizations and the need for intensive care associated with influenza pneumonia. VE was significantly higher against A (H1N1)pdm09 and was low against A (H3N2) and B.
针对流感相关肺炎的疫苗有效性(VE)的证据因季节、地点和菌株而异。我们估计了 2015-2016 至 2017-2018 季节期间,美国住院成人流感疫苗有效性网络(HAIVEN)中,针对影像学确诊的流感相关肺炎住院的 VE。
在因急性呼吸道疾病(ARI)入住 10 家美国医院的成年人中,临床医师研究者使用入院前 3 天进行的胸部影像学报告中的关键词,对“明确/可能肺炎”进行诊断。我们使用病例对照研究设计,比较流感确诊病例和阴性对照,估计针对影像学确诊的实验室确诊流感相关肺炎的 VE。流感疫苗接种情况记录在免疫记录或自我报告中,包括日期和地点。多变量逻辑回归模型用于调整年龄、地点、季节、日历时间和其他因素。
在纳入主要分析的 4843 名因 ARI 住院的成年人中,有 266 人(5.5%)患有“明确/可能肺炎”和确诊流感。针对任何影像学确诊的流感相关肺炎住院的调整 VE 为 38%(95%置信区间 [CI],17-53%);按类型/亚型,甲型流感(H1N1)pdm09 的 VE 为 74%(95% CI,52-87%),甲型流感(H3N2)的 VE 为 25%(95% CI,-15%至 50%),乙型流感的 VE 为 23%(95% CI,-32%至 54%)。针对任何流感的重症监护治疗的调整 VE 为 57%(95% CI,19-77%)。
流感疫苗在预防成人流感相关肺炎住院和重症监护需求方面的效果适度。针对甲型流感(H1N1)pdm09 的 VE 显著更高,针对甲型流感(H3N2)和乙型流感的 VE 较低。